1-36 of 36
Keywords: cardiac hypertrophy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Articles

When the liver is in poor condition, so is the heart – cardiac remodelling in MASH mouse models

Sebastian Bott, Justine Lallement, Alice Marino, Evangelos-Panagiotis Daskalopoulos, Christophe Beauloye, Hrag Esfahani, Chantal Dessy, Isabelle Anne Leclercq
Journal: Clinical Science
Clin Sci (Lond) (2024) 138 (18): 1151–1171.
https://doi.org/10.1042/CS20240833
Published: 18 September 2024
... as an additional cardiovascular stressor for 4 weeks in 10 weeks HFD-fed foz/foz mice. Foz/foz mice with fibrosing MASH developed cardiac hypertrophy with adverse cardiac remodelling not seen in WT similarly fed the HFD. AngII caused hypertension and up-regulated the expression of genes contributing...
View article titled, When the liver is in poor condition, so is the heart – cardiac remodelling in MASH mouse models
Open the PDF for When the liver is in poor condition, so is the heart – cardiac remodelling in MASH mouse models in another window
Includes: Supplementary data
Articles

Striatin plays a major role in angiotensin II-induced cardiomyocyte and cardiac hypertrophy in mice in vivo

Joshua J. Cull, Susanna T.E. Cooper, Hajed O. Alharbi, Sonia P. Chothani, Owen J.L. Rackham, Daniel N. Meijles, Philip R. Dash, Risto Kerkelä, Neil Ruparelia, Peter H. Sugden, Angela Clerk
Journal: Clinical Science
Clin Sci (Lond) (2024) 138 (10): 573–597.
https://doi.org/10.1042/CS20240496
Published: 22 May 2024
... (STRIPAK) complexes. These place protein phosphatase 2A (PP2A) in proximity to protein kinases thereby restraining kinase activity and regulating key cellular processes. Our aim was to establish if striatins play a significant role in cardiac remodelling associated with cardiac hypertrophy and heart...
View article titled, Striatin plays a major role in angiotensin II-induced cardiomyocyte and <span class="search-highlight">cardiac</span> <span class="search-highlight">hypertrophy</span> in mice in vivo
Open the PDF for Striatin plays a major role in angiotensin II-induced cardiomyocyte and <span class="search-highlight">cardiac</span> <span class="search-highlight">hypertrophy</span> in mice in vivo in another window
Includes: Supplementary data
Articles

Cardioprotective and anti-inflammatory effects of Caveolin 1 in experimental diabetic cardiomyopathy

Wenyan Gong, Qibin Jiao, Jinghua Yuan, Hui Luo, Yingying Liu, Yuanyuan Zhang, Zhen Chen, Xiaoling Xu, Lin Bai, Xingwei Zhang
Journal: Clinical Science
Clin Sci (Lond) (2023) 137 (6): 511–525.
https://doi.org/10.1042/CS20220874
Published: 24 March 2023
... 2023 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society 2023 cardiac hypertrophy cardiac injury Caveolin 1 diabetic cardiomyopathy inflammatory fibrosis NF-κB signaling Cardiovascular disease (CVD) remains the leading cause of death among...
View article titled, Cardioprotective and anti-inflammatory effects of Caveolin 1 in experimental diabetic cardiomyopathy
Open the PDF for Cardioprotective and anti-inflammatory effects of Caveolin 1 in experimental diabetic cardiomyopathy in another window
Articles

Set7 methyltransferase roles in myocardial protection from chronic stressors

James T. Pearson
Journal: Clinical Science
Clin Sci (Lond) (2023) 137 (1): 105–108.
https://doi.org/10.1042/CS20220773
Published: 05 January 2023
... assessments of cardiac function by Lunardon and colleagues now reveal a clear role of Set7 in the regulation of the extracellular matrix composition and cardiac hypertrophy in response to chronic isoproterenol induced cardiac stress. Correspondence: James T. Pearson ( [email protected] ) 13 12...
View article titled, Set7 methyltransferase roles in myocardial protection from chronic stressors
Open the PDF for Set7 methyltransferase roles in myocardial protection from chronic stressors in another window
Articles

Cardiomyocyte BRAF is a key signalling intermediate in cardiac hypertrophy in mice

Hajed O. Alharbi, Michelle A. Hardyman, Joshua J. Cull, Thomais Markou, Susanna T.E. Cooper, Peter E. Glennon, Stephen J. Fuller, Peter H. Sugden, Angela Clerk
Journal: Clinical Science
Clin Sci (Lond) (2022) 136 (22): 1661–1681.
https://doi.org/10.1042/CS20220607
Published: 21 November 2022
...Hajed O. Alharbi; Michelle A. Hardyman; Joshua J. Cull; Thomais Markou; Susanna T.E. Cooper; Peter E. Glennon; Stephen J. Fuller; Peter H. Sugden; Angela Clerk Cardiac hypertrophy is necessary for the heart to accommodate an increase in workload. Physiological, compensated hypertrophy (e.g...
View article titled, Cardiomyocyte BRAF is a key signalling intermediate in <span class="search-highlight">cardiac</span> <span class="search-highlight">hypertrophy</span> in mice
Open the PDF for Cardiomyocyte BRAF is a key signalling intermediate in <span class="search-highlight">cardiac</span> <span class="search-highlight">hypertrophy</span> in mice in another window
Includes: Supplementary data
Articles

Set7 deletion attenuates isoproterenol-induced cardiac fibrosis and delays cardiac dysfunction

Guilherme Lunardon, Tábatha de Oliveira Silva, Caroline A. Lino, Yao Wei Lu, Juliane B. Miranda, Paula F. Asprino, Amanda de Almeida Silva, Gabrielle T. Nepomuceno, Maria Cláudia Costa Irigoyen, Marcela S. Carneiro-Ramos, Ana Paula C. Takano, Herculano da Silva Martinho, Maria Luiza M. Barreto-Chaves, Da-Zhi Wang, Gabriela P. Diniz
Journal: Clinical Science
Clin Sci (Lond) (2022) 136 (21): 1537–1554.
https://doi.org/10.1042/CS20220466
Published: 10 November 2022
... with isoproterenol displayed a decrease in Set7 activity in the heart. In addition, WT and Set7 KO mice injected with isoproterenol exhibited cardiac hypertrophy. Interestingly, Set7 deletion exacerbated cardiac hypertrophy in response to isoproterenol but attenuated myocardial fibrosis. Echocardiograms revealed...
View article titled, Set7 deletion attenuates isoproterenol-induced cardiac fibrosis and delays cardiac dysfunction
Open the PDF for Set7 deletion attenuates isoproterenol-induced cardiac fibrosis and delays cardiac dysfunction in another window
Includes: Supplementary data
Articles

A long noncoding RNA CHAIR protects the heart from pathological stress

Yanxia Qian, Mingming Zhang, Ningtian Zhou, Xiaohan Xu, Jiahui Zhang, Qiang Ding, Junhong Wang
Journal: Clinical Science
Clin Sci (Lond) (2020) 134 (13): 1843–1857.
https://doi.org/10.1042/CS20200149
Published: 17 July 2020
... ), is dynamically regulated during heart development, is expressed at low levels in embryonic hearts and accumulated at high levels in adult hearts. More interestingly, the lncRNA was down-regulated during cardiac hypertrophy and failure both in mice and humans. Importantly, loss of lncRNA CHAIR has no effects...
View article titled, A long noncoding RNA CHAIR protects the heart from pathological stress
Open the PDF for A long noncoding RNA CHAIR protects the heart from pathological stress in another window
Articles

Mechanisms linking adipose tissue inflammation to cardiac hypertrophy and fibrosis

In Collection
Adipose biology, cardiovascular and cardiometabolic disease
Sarah R. Anthony, Adrienne R. Guarnieri, Anamarie Gozdiff, Robert N. Helsley, Albert Phillip Owens, III, Michael Tranter
Journal: Clinical Science
Clin Sci (Lond) (2019) 133 (22): 2329–2344.
https://doi.org/10.1042/CS20190578
Published: 28 November 2019
...), and epicardial adipose tissue (EAT) secretome on the development and progression of cardiovascular disease (CVD), with a particular focus on cardiac hypertrophy and fibrosis. Correspondence: Michael Tranter ( [email protected] ) 25 09 2019 08 11 2019 13 11 2019 © 2019 The Author...
View article titled, Mechanisms linking adipose tissue inflammation to <span class="search-highlight">cardiac</span> <span class="search-highlight">hypertrophy</span> and fibrosis
Open the PDF for Mechanisms linking adipose tissue inflammation to <span class="search-highlight">cardiac</span> <span class="search-highlight">hypertrophy</span> and fibrosis in another window
Articles

FNDC5/Irisin inhibits pathological cardiac hypertrophy

Qing Yu, Wenxin Kou, Xu Xu, Shunping Zhou, Peipei Luan, Xiaopeng Xu, Hailing Li, Jianhui Zhuang, Jun Wang, Yifan Zhao, Yawei Xu, Wenhui Peng
Journal: Clinical Science
Clin Sci (Lond) (2019) 133 (5): 611–627.
https://doi.org/10.1042/CS20190016
Published: 01 March 2019
...Qing Yu; Wenxin Kou; Xu Xu; Shunping Zhou; Peipei Luan; Xiaopeng Xu; Hailing Li; Jianhui Zhuang; Jun Wang; Yifan Zhao; Yawei Xu; Wenhui Peng Cardiac hypertrophy is a common pathophysiological process in various cardiovascular diseases, which still has no effective therapies. Irisin is a novel...
View article titled, FNDC5&#x2F;Irisin inhibits pathological <span class="search-highlight">cardiac</span> <span class="search-highlight">hypertrophy</span>
Open the PDF for FNDC5/Irisin inhibits pathological <span class="search-highlight">cardiac</span> <span class="search-highlight">hypertrophy</span> in another window
Includes: Supplementary data
Articles

Rare mutations of ADAM17 from TOFs induce hypertrophy in human embryonic stem cell-derived cardiomyocytes via HB-EGF signaling

Yifang Xie, Anyun Ma, Boshi Wang, Rui Peng, Yingchun Jing, Deqian Wang, Richard H. Finnell, Bin Qiao, Yongming Wang, Hongyan Wang, Yufang Zheng
Journal: Clinical Science
Clin Sci (Lond) (2019) 133 (2): 225–238.
https://doi.org/10.1042/CS20180842
Published: 22 January 2019
... Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY-NC-ND) . ADAM17 cardiac hypertrophy cardiomyocytes hESCs rare mutation Tetrology of Fallot Tetralogy of Fallot (TOF) is the most common cyanotic congenital...
View article titled, Rare mutations of ADAM17 from TOFs induce hypertrophy in human embryonic stem cell-derived cardiomyocytes via HB-EGF signaling
Open the PDF for Rare mutations of ADAM17 from TOFs induce hypertrophy in human embryonic stem cell-derived cardiomyocytes via HB-EGF signaling in another window
Includes: Supplementary data
Articles

Angiotensin-(1–7) reduces cardiac effects of thyroid hormone by GSK3Β/NFATc3 signaling pathway

Nathalia Senger, Marcos Barrouin Melo, Gabriela Placoná Diniz, Maria José Campagnole-Santos, Robson Augusto Souza Santos, Maria Luiza M. Barreto-Chaves
Journal: Clinical Science
Clin Sci (Lond) (2018) 132 (11): 1117–1133.
https://doi.org/10.1042/CS20171606
Published: 05 June 2018
...)) or vehicle for 14 days. In contrast with WT rats, the TG rats did not develop cardiac hypertrophy after T3 treatment. Indeed, TG rats displayed reduced systolic blood pressure (SBP) and cardiac hyperdynamic condition induced by hyperthyroidism. Moreover, increased plasma levels of Ang II observed...
View article titled, Angiotensin-(1–7) reduces cardiac effects of thyroid hormone by GSK3Β/NFATc3 signaling pathway
Open the PDF for Angiotensin-(1–7) reduces cardiac effects of thyroid hormone by GSK3Β/NFATc3 signaling pathway in another window
Articles

Leflunomide counter akt s cardiac hypertrophy

Luciana A. Pescatore, Francisco R.M. Laurindo
Journal: Clinical Science
Clin Sci (Lond) (2018) 132 (10): 1069–1073.
https://doi.org/10.1042/CS20180228
Published: 25 May 2018
...Luciana A. Pescatore; Francisco R.M. Laurindo Cardiac hypertrophy (CH) is a major independent risk factor for heart failure and mortality. However, therapeutic interventions that target hypertrophy signaling in a load-independent way are unavailable. In a recent issue of Clinical Science (vol. 132...
View article titled, Leflunomide counter akt s <span class="search-highlight">cardiac</span> <span class="search-highlight">hypertrophy</span>
Open the PDF for Leflunomide counter akt s <span class="search-highlight">cardiac</span> <span class="search-highlight">hypertrophy</span> in another window
Articles

A77 1726 (leflunomide) blocks and reverses cardiac hypertrophy and fibrosis in mice

Zhen-Guo Ma, Xin Zhang, Yu-Pei Yuan, Ya-Ge Jin, Ning Li, Chun-Yan Kong, Peng Song, Qi-Zhu Tang
Journal: Clinical Science
Clin Sci (Lond) (2018) 132 (6): 685–699.
https://doi.org/10.1042/CS20180160
Published: 30 March 2018
...Zhen-Guo Ma; Xin Zhang; Yu-Pei Yuan; Ya-Ge Jin; Ning Li; Chun-Yan Kong; Peng Song; Qi-Zhu Tang T-cell infiltration and the subsequent increased intracardial chronic inflammation play crucial roles in the development of cardiac hypertrophy and heart failure (HF). A77 1726, the active metabolite...
View article titled, A77 1726 (leflunomide) blocks and reverses <span class="search-highlight">cardiac</span> <span class="search-highlight">hypertrophy</span> and fibrosis in mice
Open the PDF for A77 1726 (leflunomide) blocks and reverses <span class="search-highlight">cardiac</span> <span class="search-highlight">hypertrophy</span> and fibrosis in mice in another window
Includes: Supplementary data
Articles

Hypertrophied myocardium is vulnerable to ischemia/reperfusion injury and refractory to rapamycin-induced protection due to increased oxidative/nitrative stress

Lei-Lei Ma, Yang Li, Pei-Pei Yin, Fei-Juan Kong, Jun-Jie Guo, Hong-Tao Shi, Jian-Bing Zhu, Yun-Zeng Zou, Jun-Bo Ge
Journal: Clinical Science
Clin Sci (Lond) (2018) 132 (1): 93–110.
https://doi.org/10.1042/CS20171471
Published: 11 January 2018
... exerts cardioprotective effects against myocardial ischemia/reperfusion (MI/R) injury in normal animals, whether rapamycin-elicited cardioprotection is altered in the presence of LVH has yet to be determined. Pressure overload induced cardiac hypertrophied mice and sham-operated controls were exposed...
View article titled, Hypertrophied myocardium is vulnerable to ischemia/reperfusion injury and refractory to rapamycin-induced protection due to increased oxidative/nitrative stress
Open the PDF for Hypertrophied myocardium is vulnerable to ischemia/reperfusion injury and refractory to rapamycin-induced protection due to increased oxidative/nitrative stress in another window
Includes: Supplementary data
Articles

Loss of microRNA-22 prevents high-fat diet induced dyslipidemia and increases energy expenditure without affecting cardiac hypertrophy

Gabriela Placoná Diniz, Zhan-Peng Huang, Jianming Liu, Jinghai Chen, Jian Ding, Renata Inzinna Fonseca, Maria Luiza Barreto-Chaves, Jose Donato, Jr, Xiaoyun Hu, Da-Zhi Wang
Journal: Clinical Science
Clin Sci (Lond) (2017) 131 (24): 2885–2900.
https://doi.org/10.1042/CS20171368
Published: 04 December 2017
...-22) is a critical regulator of cardiac function and targets genes involved in metabolic processes. Previously, we generated miR-22 null mice and we showed that loss of miR-22 blunted cardiac hypertrophy induced by mechanohormornal stress. In the present study, we examined the role of miR-22...
View article titled, Loss of microRNA-22 prevents high-fat diet induced dyslipidemia and increases energy expenditure without affecting <span class="search-highlight">cardiac</span> <span class="search-highlight">hypertrophy</span>
Open the PDF for Loss of microRNA-22 prevents high-fat diet induced dyslipidemia and increases energy expenditure without affecting <span class="search-highlight">cardiac</span> <span class="search-highlight">hypertrophy</span> in another window
Includes: Supplementary data
Articles

DUSPs as critical regulators of cardiac hypertrophy

Douglas G. Tilley, Abdelkarim Sabri
Journal: Clinical Science
Clin Sci (Lond) (2017) 131 (2): 155–158.
https://doi.org/10.1042/CS20160766
Published: 23 December 2016
...Douglas G. Tilley; Abdelkarim Sabri This commentary highlights the research presented by Li et al. [ 15 ]. In this issue of Clinical Science , which demonstrates that dual specific phosphatase 12 (DUSP12), through JNK1/2 inhibition, alleviates cardiac hypertrophy in response to pressure overload...
View article titled, DUSPs as critical regulators of <span class="search-highlight">cardiac</span> <span class="search-highlight">hypertrophy</span>
Open the PDF for DUSPs as critical regulators of <span class="search-highlight">cardiac</span> <span class="search-highlight">hypertrophy</span> in another window
Articles

Dual specific phosphatase 12 ameliorates cardiac hypertrophy in response to pressure overload

Wei-ming Li, Yi-fan Zhao, Guo-fu Zhu, Wen-hui Peng, Meng-yun Zhu, Xue-jing Yu, Wei Chen, Da-chun Xu, Ya-wei Xu
Journal: Clinical Science
Clin Sci (Lond) (2017) 131 (2): 141–154.
https://doi.org/10.1042/CS20160664
Published: 23 December 2016
...Wei-ming Li; Yi-fan Zhao; Guo-fu Zhu; Wen-hui Peng; Meng-yun Zhu; Xue-jing Yu; Wei Chen; Da-chun Xu; Ya-wei Xu Pathological cardiac hypertrophy is an independent risk factor of heart failure. However, we still lack effective methods to reverse cardiac hypertrophy. DUSP12 is a member of the dual...
View article titled, Dual specific phosphatase 12 ameliorates <span class="search-highlight">cardiac</span> <span class="search-highlight">hypertrophy</span> in response to pressure overload
Open the PDF for Dual specific phosphatase 12 ameliorates <span class="search-highlight">cardiac</span> <span class="search-highlight">hypertrophy</span> in response to pressure overload in another window
Includes: Supplementary data
Articles

Mas receptor contributes to pregnancy-induced cardiac remodelling

Cintia do Carmo e Silva, Jônathas Fernandes Queiroz de Almeida, Larissa Matuda Macedo, Marcos Barrouin Melo, Gustavo Rodrigues Pedrino, Fernanda Cristina Alcantara dos Santos, Manoel Francisco Biancardi, Robson Augusto Souza dos Santos, Adryano Augustto Valladão de Carvalho, Elizabeth Pereira Mendes, Diego Basile Colugnati, Renata Mazaro-Costa, Carlos Henrique de Castro
Journal: Clinical Science
Clin Sci (Lond) (2016) 130 (24): 2305–2316.
https://doi.org/10.1042/CS20160095
Published: 10 November 2016
... Mendes; Diego Basile Colugnati; Renata Mazaro-Costa; Carlos Henrique de Castro Previous studies have demonstrated a protective effect of the Ang-(1–7)/Mas receptor axis on pathological cardiac hypertrophy. Also, the involvement of Mas receptor in exercise-induced cardiac hypertrophy has been suggested...
View article titled, Mas receptor contributes to pregnancy-induced cardiac remodelling
Open the PDF for Mas receptor contributes to pregnancy-induced cardiac remodelling in another window
Includes: Supplementary data
Articles

Epigenetic control of exercise training-induced cardiac hypertrophy by miR-208

Ursula Paula Renó Soci, Tiago Fernandes, Valerio Garrone Barauna, Nara Yumi Hashimoto, Gloria de Fátima Alves Mota, Kaleizu Teodoro Rosa, Maria Claudia Irigoyen, Michael Ian Philips, Edilamar Menezes de Oliveira
Journal: Clinical Science
Clin Sci (Lond) (2016) 130 (22): 2005–2015.
https://doi.org/10.1042/CS20160480
Published: 06 October 2016
...Ursula Paula Renó Soci; Tiago Fernandes; Valerio Garrone Barauna; Nara Yumi Hashimoto; Gloria de Fátima Alves Mota; Kaleizu Teodoro Rosa; Maria Claudia Irigoyen; Michael Ian Philips; Edilamar Menezes de Oliveira Aerobic exercise-induced cardiac hypertrophy (CH) is a physiological response involving...
View article titled, Epigenetic control of exercise training-induced <span class="search-highlight">cardiac</span> <span class="search-highlight">hypertrophy</span> by miR-208
Open the PDF for Epigenetic control of exercise training-induced <span class="search-highlight">cardiac</span> <span class="search-highlight">hypertrophy</span> by miR-208 in another window
Articles

Tripartite motif 32 prevents pathological cardiac hypertrophy

Lijuan Chen, Jia Huang, Yanxiao Ji, Xiaojing Zhang, Pixiao Wang, Keqiong Deng, Xi Jiang, Genshan Ma, Hongliang Li
Journal: Clinical Science
Clin Sci (Lond) (2016) 130 (10): 813–828.
https://doi.org/10.1042/CS20150619
Published: 01 April 2016
... (limb girdle muscular dystrophy 2H). However, whether TRIM32 is involved in cardiac hypertrophy induced by biomechanical stresses and neurohumoral mediators remains unclear. We generated mice and isolated NRCMs (neonatal rat cardiomyocytes) that overexpressed or were deficient in TRIM32 to investigate...
View article titled, Tripartite motif 32 prevents pathological <span class="search-highlight">cardiac</span> <span class="search-highlight">hypertrophy</span>
Open the PDF for Tripartite motif 32 prevents pathological <span class="search-highlight">cardiac</span> <span class="search-highlight">hypertrophy</span> in another window
Articles

Emerging importance of chemokine receptor CXCR3 and its ligands in cardiovascular diseases

Raffaele Altara, Marco Manca, Rita D. Brandão, Asad Zeidan, George W. Booz, Fouad A. Zouein
Journal: Clinical Science
Clin Sci (Lond) (2016) 130 (7): 463–478.
https://doi.org/10.1042/CS20150666
Published: 17 February 2016
... has revealed the participation of CXCR3 and its ligands in multiple cardiovascular diseases (CVDs) of different aetiologies including atherosclerosis, hypertension, cardiac hypertrophy and heart failure, as well as in heart transplant rejection and transplant coronary artery disease (CAD). CXCR3...
View article titled, Emerging importance of chemokine receptor CXCR3 and its ligands in cardiovascular diseases
Open the PDF for Emerging importance of chemokine receptor CXCR3 and its ligands in cardiovascular diseases in another window
Articles

Atrial natriuretic peptide gene variants and circulating levels: implications in cardiovascular diseases

Speranza Rubattu, Sebastiano Sciarretta, Massimo Volpe
Journal: Clinical Science
Clin Sci (Lond) (2014) 127 (1): 1–13.
https://doi.org/10.1042/CS20130427
Published: 10 March 2014
... ]. Correspondence: Professor Massimo Volpe (email [email protected] ). 29 7 2013 14 11 2013 12 12 2013 © The Authors Journal compilation © 2014 Biochemical Society 2014 atrial fibrillation atrial natriuretic peptide cardiac hypertrophy gene variant heart failure NT-proANP...
View article titled, Atrial natriuretic peptide gene variants and circulating levels: implications in cardiovascular diseases
Open the PDF for Atrial natriuretic peptide gene variants and circulating levels: implications in cardiovascular diseases in another window
Articles

Fibulin-2 deficiency attenuates angiotensin II-induced cardiac hypertrophy by reducing transforming growth factor-β signalling

Hangxiang Zhang, Jing Wu, Hailong Dong, Shaukat A. Khan, Mon-Li Chu, Takeshi Tsuda
Journal: Clinical Science
Clin Sci (Lond) (2014) 126 (4): 275–288.
https://doi.org/10.1042/CS20120636
Published: 14 October 2013
...Hangxiang Zhang; Jing Wu; Hailong Dong; Shaukat A. Khan; Mon-Li Chu; Takeshi Tsuda AngII (angiotensin II) is a potent neurohormone responsible for cardiac hypertrophy, in which TGF (transforming growth factor)-β serves as a principal downstream mediator. We recently found that ablation of fibulin-2...
View article titled, Fibulin-2 deficiency attenuates angiotensin II-induced <span class="search-highlight">cardiac</span> <span class="search-highlight">hypertrophy</span> by reducing transforming growth factor-β signalling
Open the PDF for Fibulin-2 deficiency attenuates angiotensin II-induced <span class="search-highlight">cardiac</span> <span class="search-highlight">hypertrophy</span> by reducing transforming growth factor-β signalling in another window
Articles

The protective effects of exercise and phosphoinositide 3-kinase (p110α) in the failing heart

Kate L. Owen, Lynette Pretorius, Julie R. McMullen
Journal: Clinical Science
Clin Sci (Lond) (2009) 116 (5): 365–375.
https://doi.org/10.1042/CS20080183
Published: 02 February 2009
... effects of PI3K(p110α) in the failing heart and its potential as a therapeutic strategy for the treatment of heart failure is discussed. Correspondence: Dr Julie R. McMullen (email [email protected] ). 2 6 2008 31 7 2008 11 8 2008 cardiac hypertrophy exercise...
View article titled, The protective effects of exercise and phosphoinositide 3-kinase (p110α) in the failing heart
Open the PDF for The protective effects of exercise and phosphoinositide 3-kinase (p110α) in the failing heart in another window
Articles

MicroRNAs: role in cardiovascular biology and disease

Chunxiang Zhang
Journal: Clinical Science
Clin Sci (Lond) (2008) 114 (12): 699–706.
https://doi.org/10.1042/CS20070211
Published: 14 May 2008
.... Modulating these aberrantly expressed miRNAs has significant effects on cardiac hypertrophy, vascular neointimal lesion formation and cardiac arrhythmias. Identifying the roles of miRNAs and their target genes and signalling pathways in cardiovascular disease will be critical for future research. miRNAs may...
View article titled, MicroRNAs: role in cardiovascular biology and disease
Open the PDF for MicroRNAs: role in cardiovascular biology and disease in another window
Articles

Activation of the right ventricular endothelin (ET) system in the monocrotaline model of pulmonary hypertension: response to chronic ETA receptor blockade

Jean-François JASMIN, Peter CERNACEK, Jocelyn DUPUIS
Journal: Clinical Science
Clin Sci (Lond) (2003) 105 (6): 647–653.
https://doi.org/10.1042/CS20030139
Published: 01 December 2003
... with monocrotaline (60 mg/kg intraperitoneal) or saline, followed with treatment with the selective ET A receptor antagonist LU135252 (LU; 50 mg·kg -1 ·day -1 ) or with saline. After 3 weeks, haemodynamics, cardiac hypertrophy, ET-1 levels and cardiopulmonary ET-receptor-binding profile were evaluated. Monocrotaline...
View article titled, Activation of the right ventricular endothelin (ET) system in the monocrotaline model of pulmonary hypertension: response to chronic ETA receptor blockade
Open the PDF for Activation of the right ventricular endothelin (ET) system in the monocrotaline model of pulmonary hypertension: response to chronic ETA receptor blockade in another window
Articles

Peroxisome proliferator-activated receptor-γ activators inhibit endothelin-1-related cardiac hypertrophy in rats

Satoshi SAKAI, Takashi MIYAUCHI, Yoko IRUKAYAMA-TOMOBE, Takehiro OGATA, Katsutoshi GOTO, Iwao YAMAGUCHI
Journal: Clinical Science
Clin Sci (Lond) (2002) 103 (s2002): 16S–20S.
https://doi.org/10.1042/CS103S016S
Published: 01 September 2002
...Satoshi SAKAI; Takashi MIYAUCHI; Yoko IRUKAYAMA-TOMOBE; Takehiro OGATA; Katsutoshi GOTO; Iwao YAMAGUCHI Endothelin-1 (ET-1) causes cardiac hypertrophy, and ET receptor antagonists inhibit the development of cardiac hypertrophy in vitro and in vivo . Peroxisome proliferator-activated receptor γ...
View article titled, Peroxisome proliferator-activated receptor-γ activators inhibit endothelin-1-related <span class="search-highlight">cardiac</span> <span class="search-highlight">hypertrophy</span> in rats
Open the PDF for Peroxisome proliferator-activated receptor-γ activators inhibit endothelin-1-related <span class="search-highlight">cardiac</span> <span class="search-highlight">hypertrophy</span> in rats in another window
Articles

Factors determining cardiac hypertrophy in hypertensive patients with or without peripheral vascular disease

M. BRAHIMI, B. I. LEVY, M. E. SAFAR, H. DABIRÉ
Journal: Clinical Science
Clin Sci (Lond) (1998) 95 (3): 261–267.
https://doi.org/10.1042/cs0950261
Published: 01 September 1998
...M. BRAHIMI; B. I. LEVY; M. E. SAFAR; H. DABIRÉ 1. Coronary ischaemic disease and congestive heart failure are the principal causes of mortality in patients with peripheral vascular disease. Whether cardiac hypertrophy is present and even more pronounced in peripheral vascular disease than in other...
View article titled, Factors determining <span class="search-highlight">cardiac</span> <span class="search-highlight">hypertrophy</span> in hypertensive patients with or without peripheral vascular disease
Open the PDF for Factors determining <span class="search-highlight">cardiac</span> <span class="search-highlight">hypertrophy</span> in hypertensive patients with or without peripheral vascular disease in another window
Articles

Differential Regulation of Ventricular Adrenomedullin and Atrial Natriuretic Peptide Gene Expression in Pressure and Volume Overload in the Rat

Michael Kaiser, Ole Kahr, Yasuyuki Shimada, Pamela Smith, Martin Kelly, Harin Mahadeva, Matthew Adams, David Lodwick, Christian Aalkjaer, Metin Avkiran, Nilesh J. Samani
Journal: Clinical Science
Clin Sci (Lond) (1998) 94 (4): 359–365.
https://doi.org/10.1042/cs0940359
Published: 01 April 1998
... by left coronary ligation at 30 days post-surgery and (b) in rats with pressure-related cardiac hypertrophy induced by aortic banding at several time points (0.5, 1 and 4 h, and 1, 4, 7 and 28 days) after surgery. Levels were compared with those in matched sham-operated controls. 3. The mRNA level...
View article titled, Differential Regulation of Ventricular Adrenomedullin and Atrial Natriuretic Peptide Gene Expression in Pressure and Volume Overload in the Rat
Open the PDF for Differential Regulation of Ventricular Adrenomedullin and Atrial Natriuretic Peptide Gene Expression in Pressure and Volume Overload in the Rat in another window
Articles

Hypertension and Cardiac Hypertrophy in Growth Hormone-Deficient Rats

Stephen B. Harrap, Shari R. Datodi, Emma K. Crapper, Leon A. Bach
Journal: Clinical Science
Clin Sci (Lond) (1994) 87 (2): 239–243.
https://doi.org/10.1042/cs0870239
Published: 01 August 1994
... cardiac hypertrophy accompanying hypertension are not affected by growth hormone deficiency. 8 10 1993 28 2 1994 17 3 1994 © 1994 The Biochemical Society and the Medical Research Society 1994 Blood pressure cardiac hypertrophy dwarfism growth hormone insulin-like growth...
View article titled, Hypertension and <span class="search-highlight">Cardiac</span> <span class="search-highlight">Hypertrophy</span> in Growth Hormone-Deficient Rats
Open the PDF for Hypertension and <span class="search-highlight">Cardiac</span> <span class="search-highlight">Hypertrophy</span> in Growth Hormone-Deficient Rats in another window
Articles

Haemodynamic and Neurohumoral Changes in Spontaneously Hypertensive Rats with Aortocaval Fistulae

Tamiko Oka, Hikaru Nishimura, Masakuni Ueyama, Jiro Kubota, Keishiro Kawamura
Journal: Clinical Science
Clin Sci (Lond) (1993) 84 (5): 531–535.
https://doi.org/10.1042/cs0840531
Published: 01 May 1993
...Tamiko Oka; Hikaru Nishimura; Masakuni Ueyama; Jiro Kubota; Keishiro Kawamura 1. Our aim was to evaluate the effects of an aortocaval fistula (1 mm) on cardiorenal haemodynamics, cardiac hypertrophy and neurohumoral factors in spontaneously hypertensive rats and to compare the results with those...
View article titled, Haemodynamic and Neurohumoral Changes in Spontaneously Hypertensive Rats with Aortocaval Fistulae
Open the PDF for Haemodynamic and Neurohumoral Changes in Spontaneously Hypertensive Rats with Aortocaval Fistulae in another window
Articles

Model-based determination of cut-off values for left ventricular hypertrophy from echocardiographic myocardial mass data

Daniel Morvan, Jean-Louis Golmard, Michel Komajda, Gérard Drobinski
Journal: Clinical Science
Clin Sci (Lond) (1992) 82 (1): 25–32.
https://doi.org/10.1042/cs0820025
Published: 01 January 1992
... The Biochemical Society and the Medical Research Society 1992 cardiac hypertrophy left ventricular mass non-linear model Clinical Science (1992) 82, 25-32 (Printed in Great Britain) Model-based determination of cut-off values for left ventricular hypertrophy from echocardiographic myocardial mass data...
View article titled, Model-based determination of cut-off values for left ventricular hypertrophy from echocardiographic myocardial mass data
Open the PDF for Model-based determination of cut-off values for left ventricular hypertrophy from echocardiographic myocardial mass data in another window
Articles

Factors Influencing Cardiac Hypertrophy in Hypertensive Patients

M. Mohsen Ibrahim, M. Aziz Madkour, Ragaa Mossallam
Journal: Clinical Science
Clin Sci (Lond) (1981) 61 (s7): 105s–108s.
https://doi.org/10.1042/cs061105s
Published: 01 December 1981
... to influence significantly the regression of hypertensive left ventricular hypertrophy. © 1981 The Biochemical Society and the Medical Research Society 1981 atenolol cardiac hypertrophy echocardiography hypertension Clinical Science (1981) 61, 105s-108s 105s Factors influencing cardiac...
View article titled, Factors Influencing <span class="search-highlight">Cardiac</span> <span class="search-highlight">Hypertrophy</span> in Hypertensive Patients
Open the PDF for Factors Influencing <span class="search-highlight">Cardiac</span> <span class="search-highlight">Hypertrophy</span> in Hypertensive Patients in another window
Articles

Cardiac Sympathetic Nerves as the Final Common Pathway in the Induction of Adaptive Cardiac Hypertrophy

Ingegerd östman-Smith
Journal: Clinical Science
Clin Sci (Lond) (1981) 61 (3): 265–272.
https://doi.org/10.1042/cs0610265
Published: 01 September 1981
...Ingegerd östman-Smith © 1981 The Biochemical Society and the Medical Research Society 1981 β-adrenoceptor aortic stenosis cardiac hypertrophy coarctation hypertension noradrenaline sympathetic nerves Clinical Science (1981) 61,265-272 265 EDITORIAL REVIEW Cardiac sympathetic...
View article titled, Cardiac Sympathetic Nerves as the Final Common Pathway in the Induction of Adaptive <span class="search-highlight">Cardiac</span> <span class="search-highlight">Hypertrophy</span>
Open the PDF for Cardiac Sympathetic Nerves as the Final Common Pathway in the Induction of Adaptive <span class="search-highlight">Cardiac</span> <span class="search-highlight">Hypertrophy</span> in another window
Articles

Effect of β-Receptor-Blocking Agents on Cardiovascular Structural Changes in Spontaneous and Noradrenaline-Induced Hypertension in Rats

Yukio Yamori, R. C. Tarazi, Akira Ooshima
Journal: Clinical Science
Clin Sci (Lond) (1980) 59 (s6): 457s–460s.
https://doi.org/10.1042/cs059457s
Published: 01 December 1980
... cardiac hypertrophy hypertension isoprenaline noradrenaline osmotic minipump α- or β-receptor-blocking agents Clinical Science (1980) 5 9 , 4 5 7 ~ 4 6 0 s 457s Effect of P-receptor-blocking agents on cardiovascular structural changes in spontaneous and noradrenaline-induced hypertension in rats Y...
View article titled, Effect of β-Receptor-Blocking Agents on Cardiovascular Structural Changes in Spontaneous and Noradrenaline-Induced Hypertension in Rats
Open the PDF for Effect of β-Receptor-Blocking Agents on Cardiovascular Structural Changes in Spontaneous and Noradrenaline-Induced Hypertension in Rats in another window
Articles

Cardiac Effects of Angiotensin Antagonists in Normotensive Rats

S. Sen, R. C. Tarazi, F. M. Bumpus
Journal: Clinical Science
Clin Sci (Lond) (1979) 56 (5): 439–443.
https://doi.org/10.1042/cs0560439
Published: 01 May 1979
...S. Sen; R. C. Tarazi; F. M. Bumpus 1. Angiotensin II (AII) antagonists, namely Sar 1 ,Ile 8 -AII, Sar 1 ,Ala 8 -AII and Sar 1 ,Thr 8 -AII, were administered daily for 4 weeks to normotensive rats to study their effect on cardiac hypertrophy. 2. None of the antagonists altered blood pressure...
View article titled, Cardiac Effects of Angiotensin Antagonists in Normotensive Rats
Open the PDF for Cardiac Effects of Angiotensin Antagonists in Normotensive Rats in another window